CanSino Biologics (STU:CJH) Total Liabilities : €399.84 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Total Liabilities?

CanSino Biologics's Total Liabilities for the quarter that ended in Dec. 2024 was €399.84 Mil.

CanSino Biologics's quarterly Total Liabilities declined from Mar. 2024 (€442.30 Mil) to Jun. 2024 (€393.77 Mil) but then increased from Jun. 2024 (€393.77 Mil) to Dec. 2024 (€399.84 Mil).

CanSino Biologics's annual Total Liabilities declined from Dec. 2022 (€571.86 Mil) to Dec. 2023 (€517.74 Mil) and declined from Dec. 2023 (€517.74 Mil) to Dec. 2024 (€399.84 Mil).

CanSino Biologics Total Liabilities Historical Data

The historical data trend for CanSino Biologics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Total Liabilities Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

85.13

462.18

571.86

517.74

399.84

CanSino Biologics Quarterly Data
	Dec16	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial														489.49	517.74	442.30	393.77	399.84

CanSino Biologics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CanSino Biologics's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	232.436	+	(145.757	+	21.643
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	399.84

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	1043.858	-	644.022
	=	399.84

CanSino Biologics's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	232.436	+	(145.757	+	21.643
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	399.84

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	1043.858	-	644.022
	=	399.84

CanSino Biologics Total Liabilities Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (STU:CJH) » Definitions » Total Liabilities

Traded in Other Exchanges

CASBF:USA 06185:Hong Kong CJH:Germany 688185:China

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.

CanSino Biologics Headlines

No Headlines